NAFLD (non-alcoholic fatty liver disease) is defined as an accumulation of excess fat in the liver, in the form of triglycerides. It can be considered to be a risk condition for developing NASH (non-alcoholic steatohepatitis). NAFLD prevalence, which is rapidly rising in developed countries, is around 25% for the general population, but it reaches 50% in patients with dyslipidemia, 50% to 70% in diabetic patients and 90% in morbidly obese patients.
VAL-63 NAFLD was specially developed as a preventive solution for NASH. Its formula particularly benefits from the active ingredient TOTUM-63, which has been proven to reduce liver triglycerides by approximately 50% (preclinical data), and is also perfectly safe for clinical use.
Approximately 40% of patients with NAFLD will develop NASH, which has become one of the most common reasons for undergoing a liver transplant.